IDO1 and metastatic melanoma: Epacadostat, a potent IDO1 catalytic inhibitor, demonstrated good efficacy in preclinical and early clinical trials [82] but did not show extra benefit when combined with pembrolizumab in Phase III randomized trials for metastatic melanoma [83].